On October 14, 2024, Juncell Therapeutics announced the kick-off meeting for An Open, Single-armed, Phase Ib Study to Evaluate the Safety and Efficacy Using Autologous TIL in Patients With Non-Small Cell Lung Cancer was successfully held in both online and offline at the leading institution, Shanghai Chest Hospital. 

The meeting was attended by Professor Shun Lu, Director Ziming Li from the Department of Oncology, Director Tianqing Chu from the Drug Clinical Trial Institution, and the relevant clinical research team of Shanghai Chest Hospital, as well as Mr. Lin Shuwei, Vice President of Juncell Therapeutics, and the company's clinical medical team.

This is the first registered clinical trial in China specifically for lung cancer with TIL therapy, and it also marks another significant advancement for Juncell Therapeutics in expanding the indications of solid tumors. 

About GC101 

GC101 is an autologous natural TIL TIL therapy developed leveraging Juncell Therapeutics' proprietary DeepTIL™ cell expansion platform. DeepTIL™ enables TILs to be potent enough that no IL-2 combination will be required after infusion, and the intensity of pretreatment could be lower. 

As the first TIL therapy which only needs low-intensity pre-treatment and no IL-2 injection in the world, GC101 has been validated for its clinical efficacy and safety which greatly improves the safety and accessibility of TIL therapy. 

About MIZAR-005 

MIZAR-005 is an open-label, single-arm, Phase Ib clinical trial evaluating the safety and efficacy of autologous natural tumor infiltrating lymphocyte injection (GC101 TIL) in patients with advanced non-small cell lung cancer (NSCLC).